Camrelizumab in Combination With Apatinib and Temozolomide as First-line Treatment in Advanced Acral Melanoma

Sponsor
Peking University Cancer Hospital & Institute
Study ID
NCT05789043
Phase
PHASE3
Status
Recruiting
Apply to this trial

Conditions

  • Acral Melanoma

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

It is a RCT aimed to evaluate the Progression Free Survival of Camrelizumab combined with apatinib and temozolomide as First Line Therapy in Advanced Acral Melanoma.

Key Dates

Start date
Mar 21, 2023
Status verified
Sep 2023
Primary completion
Aug 15, 2026
Completion
Feb 15, 2027

Study Design

Enrollment
140 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Three-drug arm
  • Active Comparator: Two-drug arm
  • Active Comparator: single-drug arm

Primary Outcome Measure

Progression Free Survival, PFS [ Time Frame: Within 2 years ]

Central Contacts

Related Studies